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Methods-Results: We retrospectively analyzed clinical, hematological, and angio-
graphic data of 201 patients (mean age 59.813.1 years, 74.6% men) who had
undergone PCI for acute STEMI and a further control coronary angiography due to
stable angina pectoris or acute coronary syndrome. Patients were divided into two
groups according to developing stent thrombosis (n¼147) or not (n¼54). Age, sex,
hemoglobin, C-reactive protein, stent type and length, pre and post-dilatation of the
stent did not differ between groups. The pre-procedural PLR was signiﬁcantly higher
in patients with stent thrombosis compared to patients without stent thrombosis
(17668 vs. 13562; p<0.001). The NLR was positively correlated with PLR
(r:0.623, p<0.001) but did not differ between two groups (p¼0.702) After multiple
logistic regression analysis, pre-procedural PLR remained signiﬁcant predictor of stent
thrombosis (OR: 1.009, 95% conﬁdence interval: 1.004-1.014, p<0.001). In receiver
operating characteristics analysis, the PLR> 150 had 63% sensitivity and 70%
speciﬁcity in predicting stent thrombosis.
Conclusıon: High pre-procedural PLR is a signiﬁcant and independent predictor of
stent thrombosis in patients with acute STEMI.Clinical, biochemical, hematological and procedural characteristics of
patients based on the presence of stent thrombosis
Variable
Stent thrombosis
absent n¼147
Stent thrombosis
present n¼54 p value
Age, years 60.5  13.5 57.9  11.9 0.202
Male sex, n (%) 110 (74.8) 40 (74.1) 0.913
Hypertension, n (%) 49 (33.3) 25 (46.3) 0.091
Diabetes Mellitus,
n (%)
30 (20.4) 12 (22.2) 0.775
Smoking, n (%) 76 (51.7) 26 (48.1) 0.655
Glucose, mg/dl 157  73 158  90 0.202
Creatinine, mg/dl 0.89  0.21 0.86  0.20 0.408
C-reactive protein,
mg/dl
0.66  0.40 0.77  0.33 0.109
Total cholesterol,
mg/dl
171  38 170  38 0.872
High-density
lipoprotein, mg/dl
35  9 35  9 0.933
Low-density
lipoprotein, mg/dl
108  29 104  29 0.369
Hemoglobin, g/L 14.0  1.2 14.2  1.5 0.455
Platelet count,
x109/L
251  63 293  71 <0.001
White blood cell
count, x109/L
12.20  2.82 11.55  2.86 0.152
Neutrophil count,
x109/L
9.20  2.72 8.83  2.83 0.361
Lymphocyte count,
x109/L
2.13  0.90 1.85  0.63 0.077
Neutrophil to
lymphocyte ratio
5.09  2.73 5.60  3.50 0.702
Platelet to
lymphocyte ratio
135  62 176  68 <0.001
Drug eluting stents,
n (%)
61 (41.5) 20 (37) 0.568
Stent diameter,
mm
3.0  0.4 3.0  0.4 0.980
Stent length, mm 22.15  5.65 22.98  6.62 0.533
Pre-dilatation, n (%) 118 (80.3) 44 (81.5) 0.848
Post-dilatation, n
(%)
80 (54.4) 29 (53.7) 0.928
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Introductıon: Endo-derived nitric oxide (NO) is synthesizes from L-arginine by
endothelial nitric oxide synthase (NOS3). Reduction in basal NO relase is known toJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTpredispoze thrombosis. Stent trombosis is related to defects in generation or fonction
of NO. The aim of this study was to investigate the relationship between the
Glu298Asp polymorphism and stent thrombosis.
Patients and Method: The study was included in patient who devoloped stent
thrombosis (77) and who undeveloped stent thrombosis (31) after stent placement in
Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and
Research Hospital, Department of Cardiology.
Results: Glu298Asp polymorphism of the study and control groups were no signif-
icant differences between the distributions of GG (p¼0.860), GT (p¼0.970), TT
(p¼0.838). Acute, subacute, late and very late stent thrombosis period, there wasn't
any statistically signiﬁcant difference between the groups of the distribution of
Glu298Asp (p¼0.478). There was no signiﬁcant difference in the distribution of
polymorphism Glu298Asp between the groups of acute (p¼0.533), subacute
(p¼0.469), late (p¼0.975) and very late (p¼0.975) stent trombosis and the control
group.
Conclusıon: Acquired defects in the formation of NO are associated in increased risk
factors of cardiovascular disease NO concentrations ﬂuctuate on a regular basis. Its
low concentrations are favorable and high concentrations have a toxic effect. Either
the decrease in the activity of NOS or over-stimulation of NO may play a role in the
development of stent trombosis. The deterioration of eNOS activity may play a role in
the development of stent thrombosis, suggesting that the publications available. In our
study, analysis of patients with and without stent thrombosis, endothelial nitric oxide
synthase Glu298Asp gene polymorphism was not signiﬁcantly different. According to
the time of stent thrombosis developed was classiﬁed as acute, subacute, late and too
late there was not a signiﬁcant different between the time of stent trombosis in the
patients with the Glu298Asp gene polymorphism.
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Objectıves: In this study, we evaluated distribution of atrial septal defect (ASD) types
which were diagnosed by transesophageal echocardiography (TEE). Also we evalu-
ated shunt ratio with cardiac catheterization and investigated results of percutaneous
closure of secundum ASD in our clinic.
Method and Results:We retrospectively evaluated 163 ASD cases between 2005 and
2013. The mean age of the patients was 36.715.1 (year), female/male ratio was; 111
(68.1%) / 52 (31.9%9). 119 (73%) cases were ostium secundum type, 29 (17.8%)
cases were sinüs venosus type (21 cases superior vena cava type, 8 cases inferior vena
cava type), 14 (8.6%) cases were ostium primum type and 1 (0.6%) case was coronary
sinüs type ASD. 89 cases were treated with surgery, 58 cases were treated with
pecutaneous tecnique and 16 cases were treated medically after cardiac catheteriza-
tion. Mean age of the secundum ASD cases which treated with percutaneous tecnique
was 36.514.9 (year) and according to TEE measurement, mean defect diameter was:
20.314.6 mm, mean anterior superior rim was: 4.83.4 mm, mean anterior inferior
rim was:18.316.9 mm, mean posterior superior rim was: 20.815.4 mm, mean
posterior inferior rim was: 17.70.8 mm. According to cardiac catheterization the
cases mean Qp/Qs ratio was: 2.31.0. Device size used for percutaneous closure of
ASD was: 22.86.8 mm. Devices used for percutaneous closure were Amplatzer
46.6% (27 cases), Lifetech 31% (18 cases), Cardioﬁx 12.1% (7 cases) and other 10.3%
(6 cases). We never used double device for the cases. The percutaneous closure
procedure was successful at 57 of 58 (98.2%) patients. In 1 patient procedure was
failed, because the device was not stabile with Minnesota maneuver, so the patient
referred to surgery. During follow up 1 more patient referred to surgery because of
device embolization and we showed residuel shunt in 1 patient in ﬁrst day control.
Thrombus on devices, device erosion or death is not observed after the procedure.
Conclusıon: Distribution of atrial septal defect types in young Turkish popülation
was; respectively: secundun ASD, sinüs venosus ASD and ostium primum ASD.
Percutaneous closure of secundum ASD which replaced surgical treatment of
secundum ASD is safe and effective method. However because of potentially serious
complication risks it should be performed in special centers which are experienced in
treating ASD.
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Because of the length of the lesion in chronic total occlusions (CTO), sometimes
more than one stents are used and a metal jacket is prepared. The application of
bioresorbable scaffolds in such lesions appears quite attractive. However, the use of
these devices may be limited due to former occlusions in CTOs and as most of them
may contain serious calciﬁcations. Excluding a case presentation published in the
literature of BCS use in CTO, there is no any data.ERS C231
